StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > ASCO 2021

<< Previous

Bullboard Posts

Next >>

Comment by LithLoveron May 20, 2021 10:51am

77 Views

Post# 33237353

RE:RE:ASCO 2021

The only thing that wasn't great with the financials was the warrant valuation but again thats only on paper.

So imagine next quarter they have a similar covid revenue (maybe a little less from employer groups but more from airlines and Rexall). Add in Aristotle testing started at Care Oncology. For fun lets say the same quarter revenue in Q2 as Q1.

EBITDA would be positive, cash flow positive, cash holdings little change and if warrant valuation stays flat that would be a great quarter.

Close the Care Oncology deal which means their revenues from clinic and treatments flows into stage for Q3 and on.

No way this can stay at this level.

Just need to keep pushing the marketing and some updates on Care Oncology.